The most important data release in metabolic peptide research in 2026 arrived at the American Diabetes Association Scientific Sessions in New Orleans in June — and it has reshaped the research conversation around R3TA in Australia completely. TRIUMPH-1 full data confirmed what Phase 2 had suggested: Retatrutide is not incrementally better than existing GLP-1 compounds. It is categorically different. Here is what the data shows and what it means for Australian researchers.
What Is TRIUMPH-1?
TRIUMPH-1 is the pivotal Phase 3 master trial for Retatrutide in adults with obesity or overweight and at least one weight-related comorbidity, without type 2 diabetes. It is the largest and most definitive trial in the TRIUMPH programme — enrolling 2,339 adults randomised 1:1:1:1 to Retatrutide at 4mg, 9mg, or 12mg, or placebo, in a randomised double-blind placebo-controlled design.
The 80-week trial duration is significant. Most Phase 2 data — including the 24.2% weight loss figure that first captured global attention — was measured at 48 weeks. TRIUMPH-1 extends that window by 32 weeks, giving researchers a far more complete picture of Retatrutide’s sustained efficacy and long-term safety profile.
At 80 weeks, participants on 4mg of Retatrutide lost an average of 17.6% of their body weight, compared with 23.7% on 9mg, 25.0% on 12mg, and 3.9% on placebo.
Those taking the 12mg dose lost an average of 28.3% of body weight — approximately 70 pounds — compared with 2.2% in the placebo group, while 45.3% of participants achieved 30% or greater weight loss.
To contextualise these numbers for Australian researchers: tirzepatide — currently the most efficacious approved weight loss compound — achieved approximately 20-21% weight loss in its landmark SURMOUNT-1 trial at comparable timepoints. Retatrutide’s 28.3% at 80 weeks on the 12mg dose represents a meaningfully different efficacy ceiling — driven by the glucagon receptor activation that no approved dual agonist delivers.
The 45.3% of participants achieving 30% or greater weight loss is perhaps the most striking single figure in the dataset. At that level of weight reduction, researchers are no longer studying modest metabolic improvement — they are studying outcomes that approach those previously achievable only through bariatric surgery.
TRIUMPH-1 was not just a weight loss trial. The cardiometabolic secondary endpoints are among the most important findings in the full dataset — and they have significant implications for researchers working beyond pure obesity biology.
In TRIUMPH-1, Retatrutide was associated with reductions of up to 41.0% in triglycerides, 24.2% in non-HDL cholesterol, 12.3 mm Hg in systolic blood pressure, and 24.1 cm in waist circumference at 80 weeks.
Each of these figures deserves individual attention:
Triglycerides down 41.0%: Hypertriglyceridaemia is one of the most prevalent and undertreated components of metabolic syndrome in Australia. A 41% reduction from a single weekly injection — driven substantially by the glucagon receptor’s hepatic fat metabolism effects — is a finding with significant implications for cardiovascular risk research.
Non-HDL cholesterol down 24.2%: Non-HDL cholesterol is now recognised as a superior cardiovascular risk predictor to LDL cholesterol alone, because it captures the full spectrum of atherogenic lipoproteins. A 24.2% reduction across the trial population represents a clinically meaningful cardiovascular risk modification signal.
Systolic blood pressure down 12.3 mmHg: A reduction of this magnitude, if sustained, corresponds to meaningful reductions in stroke, myocardial infarction, and heart failure risk at the population level — extending Retatrutide’s research relevance well into cardiovascular medicine.
Waist circumference down 24.1cm: Central adiposity — measured by waist circumference — is the metabolic risk marker most directly linked to visceral fat and insulin resistance. A 24.1cm reduction represents a fundamental shift in the participant’s metabolic phenotype, not just a cosmetic weight loss outcome.
TRIUMPH-1 included two nested basket trials within the master study — providing additional data on two of the most prevalent and burdensome obesity-related conditions in Australia.
In the nested osteoarthritis basket of 574 participants with knee osteoarthritis, the results demonstrated substantial improvements in osteoarthritis-related symptoms, including a striking finding that one in eight participants treated with Retatrutide reported complete resolution of knee pain by the end of the trial.
Complete resolution of knee pain — not just improvement, but complete resolution — in one in eight participants treated with a metabolic peptide. This finding alone positions Retatrutide as one of the most significant compounds in musculoskeletal medicine research, with implications extending far beyond the obesity research community.
In the nested sleep apnoea basket of 243 participants with moderate to severe obstructive sleep apnoea, Retatrutide demonstrated significant improvements across sleep apnoea severity measures — adding to the growing body of evidence that obesity-driven sleep apnoea is tractably addressable through metabolic intervention at the receptor level.
Safety was characterised by dose-related nausea, diarrhoea, constipation, and vomiting — the established gastrointestinal side effect profile of the incretin class — alongside dysesthesia and urinary tract infections that were typically mild to moderate.
Common gastrointestinal side effects were observed but were generally mild and infrequently led to discontinuation.
Overall treatment discontinuation rates were similar across the Retatrutide and placebo treatment arms. Discontinuation rates due to adverse events were 12.2% and 18.2% with Retatrutide 9mg and 12mg respectively, compared to 4.0% with placebo — and these rates were highly correlated with baseline BMI, with lower discontinuation rates in participants with BMI 35 or above.
For researchers, the discontinuation data provides important context for protocol design — the 12mg dose produces stronger efficacy but higher discontinuation rates, with the 9mg dose representing a potentially more practically viable research target for extended protocols.
The TRIUMPH-1 full dataset establishes several things that are directly relevant to Australian researchers:
The efficacy signal is durable at 80 weeks. Phase 2’s 48-week data was compelling but raised questions about whether effects would be sustained. TRIUMPH-1 answers those questions — weight loss continues to accumulate through 80 weeks on all three doses, with no evidence of plateau at the 12mg level by trial end.
The cardiometabolic profile is independently significant. The triglyceride, non-HDL cholesterol, and blood pressure data mean Retatrutide is no longer just a weight loss research compound — it is a comprehensive cardiometabolic research tool with multiple independent research questions embedded in a single compound.
The dose-response relationship is clear. A clear dose-response trend appeared across the study — higher dose, stronger effect — giving researchers a well-defined parameter space for designing dose-escalation protocols.
The comparator landscape has shifted. With TRIUMPH-1 data public, the research conversation in Australia has moved from whether Retatrutide outperforms existing agents to by how much — and through which specific mechanisms the glucagon receptor co-activation produces its incremental benefit.
TRIUMPH-1 is not the end of the data flow — it is the beginning. Lilly plans to submit a Biologics License Application to the FDA in Q1 2027, with additional results from TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease) expected later in 2026.
In TRIUMPH-2, participants taking Retatrutide 12mg lost an average of 20.8% of body weight alongside HbA1c reductions of up to 1.6%. In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to an average of 22.6% at 80 weeks.
For Australian researchers, this pipeline of data means the Retatrutide evidence base will continue to deepen substantially through the remainder of 2026 — making now the most productive time to be building research protocols around this compound.
New batch COAs and restock alerts, sent when they happen.
Need more information about Peps Aussie? Get in contact with us via the email below and Peps Aussie will assist you promptly.
Include your name and a relevant subject line.
Every batch we publish a third-party certificate of analysis. Get told when a new one lands, and when a sold-out peptide is back.
